GeneDx Files IPR Petitions at USPTO against 11 Patents at Issue in Myriad Lawsuit | GenomeWeb

This article has been updated to include a statement from Myriad Genetics.

NEW YORK (GenomeWeb) – Law firm Sterne, Kessler, Goldstein & Fox announced today it has filed petitions for Inter Partes Review (IPR) with the US Patent and Trademark Office on behalf of its client GeneDx, which is seeking to nullify patents held by competitor Myriad Genetics related to gauging cancer risk based on mutations in three genes: BRCA1, BRCA2, and MUTYH.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nucleic Acids Research this week: nanopore sequencing workflow to detect antibiotic resistance in gut microbes, TSSPlant tool, and more.

Because gene-edited organisms can cross borders, Gizmodo wonders whether there should be an international body to govern their use.

HHS Secretary nominee Tom Price is to go in front of the Senate Committee on Health, Education, Labor and Pensions today, NPR's Morning Edition reports.

Prior to being closed, Theranos' Arizona lab failed an inspection by regulators, according to the Wall Street Journal.